Company profile

Emergent BioSolutions

emergentbiosolutions.comHeadquarters: United States
201-1000 employeesHybrid (Product + Service)
Emergent BioSolutions logo

Primary focus

Researches, develops, manufactures and distributes medical countermeasures and protective products.

Why it’s included

The company explicitly develops and manufactures NARCAN Nasal Spray, described as 'Naloxone HCl nasal spray for opioid overdose reversal,' and has completed its own clinical trial on intranasal naloxone, directly matching the topic's requirements for overdose reversal products.

Relevant capabilities

  • Clinical development and trial execution support
  • Biologics and plasma-derived drug substance manufacturing
  • Regulatory and quality systems for medical countermeasures
  • Government procurement, stockpile supply and emergency logistics
  • Development of medical countermeasures
Commercial sectorOverdose Reversal and Rescue Product Developers
Technology classesOpioid antagonist overdose rescue formulations

Relevant commercial products

  • NARCAN Nasal Spray

← Back to what’s inside this report